Relievant gets FDA OK for expanded back-pain-device trial

06/4/2013 | MassDevice.com (Boston)

The FDA has granted Relievant Medsystems investigational device exemption to conduct a larger clinical study of its Intracept basivertebral nerve ablation device. The 200-participant trial will be expanded to include 20 U.S. clinical sites, where the device will be tested for treating recurrent low back pain.

View Full Article in:

MassDevice.com (Boston)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY